Abstract Chromothripsis is detectable in 20–30% of newly diagnosed multiple myeloma
(NDMM) patients and is emerging as a new independent adverse prognostic factor. In this …

Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and
with time can progress to a more aggressive disease in extramedullary locations. The …

Deciphering genomic architecture is key to identifying novel disease drivers and
understanding the mechanisms underlying myeloma initiation and progression. In this work …

Abstract Analysis of the genetic basis for multiple myeloma (MM) has informed many of our
current concepts of the biology that underlies disease initiation and progression. Studying …

To obtain a comprehensive genomic profile of presenting multiple myeloma cases we
performed high-resolution single nucleotide polymorphism mapping array analysis in 114 …

Structural chromosomal changes including copy number aberrations (CNAs) are a major
feature of multiple myeloma (MM), however their evolution in context of modern biological …

The diagnosis and risk stratification of multiple myeloma (MM) is based on clinical and
cytogenetic tests. Magnetic CD138 enrichment followed by interphase FISH (fluorescence in …

Purpose Chromosomal aberrations are a hallmark of multiple myeloma but their global
prognostic impact is largely unknown. Patients and Methods We performed a genome-wide …

To explore novel genetic abnormalities occurring in myelodysplastic syndromes (MDS)
through an integrative study combining array-based comparative genomic hybridization …

Abstract Hyperhaploid clones (24–34 chromosomes) were identified in 33 patients with
multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly …